Physician profile
John R Sutherland
NPI 1134159742
$2,413.61
in general payments reported to CMS, 2019-2025
33 companies · $27.07 in 2025
The $27.07 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $106 · 2021: $471 · 2022: $612 · 2023: $350 · 2024: $70.02 · 2025: $27.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.93 |
| Education | $119.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.30 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $232.92 | 2019-2023 | |
| Pfizer INC. | $172.19 | 2019-2023 | |
| Exeltis, USA INC. | $162.53 | 2019-2023 | Slynd |
| Hologic Sales and Service, LLC | $119.84 | 2019-2023 | Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $106.76 | 2019-2021 | |
| Myovant Sciences INC. | $106.00 | 2021-2022 | |
| Medtronic USA, INC. | $105.36 | 2019 | |
| Vertical Pharmaceuticals, LLC | $88.19 | 2019 | |
| Evofem Biosciences, INC. | $80.31 | 2021-2023 | Phexxi |
| Ardelyx, INC. | $79.62 | 2024-2025 | Ibsrela |
| Amag Pharmaceuticals, INC. | $76.05 | 2019 | |
| Therapeuticsmd, INC. | $57.08 | 2019-2021 | |
| Daiichi Sankyo INC. | $56.44 | 2019-2022 | |
| Medtronic, INC. | $55.53 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $43.00 | 2019 | |
| Agile Therapeutics, INC. | $42.63 | 2022 | |
| Baxter Healthcare | $37.32 | 2021 | |
| Mayne Pharma Commercial LLC | $35.05 | 2023 | |
| Roche Diagnostics Corporation | $33.76 | 2021 | |
| Organon LLC | $32.41 | 2022-2023 | Nexplanon |
| Avion Pharmaceuticals | $28.59 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $27.13 | 2019-2020 | |
| Coopersurgical, INC. | $25.46 | 2021-2022 | |
| Duchesnay USA Incorporated | $18.38 | 2019 | |
| Intuitive Surgical, INC. | $18.36 | 2021 | |
| Sumitomo Pharma America, INC. | $17.47 | 2024 | Myfembree |
| Lupin INC. | $14.87 | 2019 | |
| Alydia Health | $14.79 | 2021 | |
| Radius Health, INC. | $14.70 | 2019 | |
| Pharmacosmos Therapeutics INC. | $14.47 | 2021 | |
| Sanofi Pasteur INC. | $13.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.